<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04422743</url>
  </required_header>
  <id_info>
    <org_study_id>NP2017</org_study_id>
    <nct_id>NCT04422743</nct_id>
  </id_info>
  <brief_title>Effect of Citicoline/Homotaurine on PERG in Primary Open Angle Glaucoma</brief_title>
  <official_title>Effect of the Fixed Combination Citicoline 500 mg Plus Homotaurine 50 mg on Pattern Electroretinogram in Well Controlled Primary Open Angle Glaucoma: A Multicenter, Prospective, Randomized, Single Blind, Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Policlinico S. Matteo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the general purpose of the study is to evaluate the potential beneficial effects of
      supplementation of a fixed combination of Citicoline 500 mg plus Homotaurine 50 mg on retinal
      ganglion cells (RGCs) function in subjects with glaucoma by pattern electroretinogram.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary objectives are to assess effects on visual acuity, visual field changes, Quality of
      Life perception (NEI VFQ25 questionnaire), and safety (Incidence of adverse events)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 25, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess effects of adding the fixed combination of Citicoline 500 mg plus Homotaurine 50 mg (Neuprozin® - NP), one tablet a day, on PERG examination at four months of therapy, compared to standard of care alone, as add-on to standard therapy</measure>
    <time_frame>4 months of therapy 2 months of wash out 4 months without adding therapy</time_frame>
    <description>changes in amplitude (microVolt)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess effects of one tablet a day of the fixed combination of Citicoline 500 mg plus Homotaurine 50 mg (Neuprozin® - NP) on visual acuity</measure>
    <time_frame>4 months of therapy 2 months of wash out 4 months without adding therapy</time_frame>
    <description>changes in visual acuity (decimals)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess effects of one tablet a day of the fixed combination of Citicoline 500 mg plus Homotaurine 50 mg (Neuprozin® - NP) on visual field</measure>
    <time_frame>4 months of therapy 2 months of wash out 4 months without adding therapy</time_frame>
    <description>changes in mean deviation (deciBell-dB) and in pattern standard deviation (deciBell-dB) of visual field parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to assess effects of one tablet a day of the fixed combination of Citicoline 500 mg plus Homotaurine 50 mg (Neuprozin® - NP) on quality of life</measure>
    <time_frame>4 months of therapy 2 months of wash out 4 months without adding therapy</time_frame>
    <description>changes in the total mean score and in the subscales of the 25 item National Eye Institute - Visual Functioning Questionnaire (NEI VFQ25) (scores are presented as a number, higher numbers reflect higher QL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>standard of care + citicoline plus homotaurine (CIT/HOMO)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CIT/HOMO was supplemented for 4 months to the standard of care (SOC, i.e. topical intraocular pressure, IOP, lowering medication)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>only standard of care (SOC, i.e. topical IOP lowering medication) for 4 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Citicoline 500 mg plus Homotaurine 50 mg</intervention_name>
    <description>Citicoline 500 mg plus Homotaurine 50 mg was added to topical therapy</description>
    <arm_group_label>standard of care + citicoline plus homotaurine (CIT/HOMO)</arm_group_label>
    <other_name>CIT/HOMO</other_name>
    <other_name>Neuprozin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 40 and 75 years;

          -  diagnosis of primary OAG (POAG) from, at least, 3 years;

          -  visual acuity &gt; 0.7 (7/10) decimals;

          -  refractive error &lt; 5 D (spheric) and &lt; 2D (toric);

          -  transparent diopter means (cornea and lens);

          -  controlled IOP (&lt;18 mmHg, morning value) with beta-blockers and prostaglandin
             analogues as monotherapy or as associative therapy (fixed or unfixed);

          -  stable IOP&lt;18 mmHg in the last 2 years;

          -  stable and unchanged topical therapy in the last 6 months;

          -  stable disease in the last 2 years (no more than -1 dB/year at MD of visual field);

          -  at least two reliable visual fields (Humphrey 24-2 Swedish interactive threshold
             algorithm -SITA- Standard) per year in the last 2 years;

          -  early to moderate visual field defect (MD &lt;12 dB);

          -  electrophysiological (PERG) parameters alterations similar to glaucomatous pathology;

          -  written consent to participate to study procedures and data utilization in an
             anonymous form

        Exclusion Criteria:

          -  ocular hypertension with normal optic nerve and visual field; angle closure glaucoma;

          -  congenital glaucoma; secondary glaucoma; normal tension glaucoma;

          -  history of recurrent uveitis/scleritis/herpes infection;

          -  pregnancy and breastfeeding;

          -  contraindication to Citicoline and/or Homotaurine

          -  contraindication to beta-blockers and prostaglandine analogues

          -  topical therapy with Brimonidine monotherapy or fixed combination (with timolol or
             brinzolamide)

          -  topical therapy with pilocarpine and aceclidine, monotherapy or fixed combination
             systemic or topical treatment with another neuroprotective agent in the last 4 months
             prior to enrollment

          -  systemic therapies affecting patients' performance in visual field examination
             (sedatives);

          -  glaucomatous scotomas within 10 degree from fixation

          -  any condition limiting the patient's ability to participate in the study;

          -  other ocular causes of visual field and PERG changes, such as cataract, myopic
             chorioretinopathy, macular diseases, retinal vascular occlusion, diabetic retinopathy;

          -  other systemic causes of visual field and PERG changes such as neurodegenerative
             disorders (Alzheimer's disease, Parkinson's disease, ALS, MS) or pituitary disorders;

          -  cerebral ischemia in the last 2 years

          -  any change in topical therapy in the 6 months prior to enrollment or during the study
             period concomitant participation to another clinical trial

          -  any previous filtering and/or retinal surgery;

          -  cataract surgery in the last 6 months;

          -  any previous laser treatment for glaucoma in the last 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>gemma caterina m Rossi</last_name>
    <role>Study Director</role>
    <affiliation>IRCCS Fondazione Policlinico San Matteo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gemma Caterina Maria Rossi</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dario Sisto</name>
      <address>
        <city>Bari</city>
        <zip>70121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberto Mavilio</name>
      <address>
        <city>Brindisi</city>
        <zip>72100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teresa Rolle</name>
      <address>
        <city>Torino</city>
        <zip>10121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Rossi, Gemma Caterina Maria</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pattern electroretinogram</keyword>
  <keyword>visual field</keyword>
  <keyword>quality of life</keyword>
  <keyword>citicoline 500 mg plus homotaurine 50 mg</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramiprosate</mesh_term>
    <mesh_term>Cytidine Diphosphate Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>data will be published on peer review journal</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>upon publication</ipd_time_frame>
    <ipd_access_criteria>actually not available</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

